Meeting
2014 ASCO Annual Meeting
MGMT gene promoter methylation in plasma of glioma patients receiving temozolomide.
Authors
Riccardo Soffietti
Department of Neuro-Oncology, University and City of Health and Science Hospital of Turin, Turin, Italy
Riccardo Soffietti , Luca Bertero , Elisa Trevisan , Anna Castiglione , Valentina Fiano , Morena Trevisan , Paola Cassoni , Franco Merletti , Roberta Ruda
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Highlights Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Central Nervous System Tumors
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr 2016)
DOI
10.1200/jco.2014.32.15_suppl.2016
Abstract #
2016
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Impact of predictive impact of MGMT promoter methylation in malignant astrocytomas depends on the methylation subgroup.
First Author: Wolfgang Wick
Poster
2018 ASCO Annual Meeting
Differential elevation of TERT activity and sensitivity to temozolomide by type of TERT mutation in MGMT promoter-methylated glioblastoma.
First Author: Michael Weller
Poster
2015 ASCO Annual Meeting
Defining the cutoff value of MGMT gene promoter methylation and its predictive capacity.
First Author: Andrea Rocca
Poster
2022 ASCO Annual Meeting
Preoperative chemoradiotherapy with capecitabine with or without temozolomide in patients with locally advanced rectal cancer: A prospective, randomized phase 2 study stratified by MGMT (O6-methylguanine DNA methyltransferase) status: KCSG-CO17-02.
First Author: Chung Ryul Oh